Overall market sentiment has been down on Actinium Pharmaceuticals Inc (ATNM) stock lately. ATNM receives a Bearish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With ATNM Stock Today?
Actinium Pharmaceuticals Inc (ATNM) stock is up 4.47% while the S&P 500 is lower by -0.47% as of 12:06 PM on Thursday, Mar 25. ATNM has risen $0.37 from the previous closing price of $8.27 on volume of 286,933 shares. Over the past year the S&P 500 is up 58.16% while ATNM has risen 49.22%. ATNM lost -$2.59 per share in the over the last 12 months.
To see the top 5 stocks in the Biotechnology industry click here.
More About Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Click Here to get the full Stock Score Report on Actinium Pharmaceuticals Inc (ATNM) Stock.
